Sector News

Returns on pharmaceutical R&D improving as pipelines revive

December 11, 2014
Life sciences
(Reuters) – Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development (R&D) increasing for the first time since 2010.
 
Overall R&D returns have improved to 5.5 percent this year from 5.1 percent in 2013, reflecting a modest uptick in productivity in company labs, according to the latest annual survey of the industry by Deloitte released on Wednesday.
 
The global pharmaceuticals sector needs to replenish its medicine chest after a wave of patent expiries that peaked in 2012, and the numbers show that pipelines are getting fuller.
 
So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world’s biggest market, has approved 35 new products, up from 27 in the whole of 2013 and close to the bumper 39 cleared in 2012, the agency’s website shows. (here)
 
There are significant variations between companies, however, with the largest firms having the greatest development costs for each new medicine and the lowest returns on R&D investment.
 
The most successful of the 12 leading drugmakers assessed in the survey had an R&D return of 11.7 percent in 2014, while the worst-performing saw a negative return of 0.7 percent.
 
“There are signs that returns from pharmaceutical R&D are turning a corner,” Julian Remnant, head of Deloitte’s European R&D advisory practice, said.
 
“However, we continue to see a relentless rise in the costs to develop a new medicine — this year to $1,401 million — with little change to the billions of dollars of value lost from products failing in the final stage of development.”
 
The companies analysed in the study were Pfizer, Roche, Novartis, Sanofi, GlaxoSmithKline, Johnson & Johnson, AstraZeneca , Merck & Co, Eli Lilly, Bristol-Myers Squibb, Takeda and Amgen.
 
Results for individual companies were not disclosed. 
 
BY BEN HIRSCHLER (Editing by Jane Merriman)

comments closed

Related News

March 2, 2024

Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024

Life sciences

After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.

March 2, 2024

Argenx goes again, ramping up unbranded campaign ahead of hoped-for label expansion

Life sciences

Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.

March 2, 2024

EuroAPI appoints new CEO and lays out restructuring plan as manufacturer’s losses mount

Life sciences

Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.

How can we help you?

We're easy to reach